

Åystein Rekdal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/269551/publications.pdf>

Version: 2024-02-01

34
papers

2,055
citations

279798

23
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

2302
citing authors

#	ARTICLE	IF	CITATIONS
1	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. <i>OncolImmunology</i> , 2021, 10, 1962592.	4.6	30
2	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2755-2763.	7.0	29
3	Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6731.	3.3	5
4	Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. <i>Trends in Cancer</i> , 2021, 7, 557-572.	7.4	33
5	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
6	Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. <i>Breast Cancer Research</i> , 2019, 21, 9.	5.0	40
7	The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 139-148.	4.4	17
8	Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 177.	0.8	12
9	Tumor lysis with LTX-401 creates anticancer immunity. <i>OncolImmunology</i> , 2019, 8, e1594555.	4.6	26
10	Recruitment of LC3 to damaged Golgi apparatus. <i>Cell Death and Differentiation</i> , 2019, 26, 1467-1484.	11.2	18
11	LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects. <i>Cell Stress</i> , 2019, 3, 348-360.	3.2	19
12	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. <i>Cell Death and Disease</i> , 2018, 9, 1086.	6.3	20
13	Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. <i>EMBO Journal</i> , 2018, 37, .	7.8	81
14	A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties. <i>Experimental Cell Research</i> , 2017, 352, 218-224.	2.6	8
15	LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. <i>Future Medicinal Chemistry</i> , 2017, 9, 1339-1344.	2.3	60
16	Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. <i>OncolImmunology</i> , 2017, 6, e1338236.	4.6	36
17	The Cytolytic Amphipathic Î²(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma. <i>PLoS ONE</i> , 2016, 11, e0148980.	2.5	14
18	The oncolytic compound LTX-401 targets the Golgi apparatus. <i>Cell Death and Differentiation</i> , 2016, 23, 2031-2041.	11.2	25

#	ARTICLE	IF	CITATIONS
19	Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2918-2927.	6.4	77
20	The oncolytic peptide LTX-315 triggers necrotic cell death. <i>Cell Cycle</i> , 2015, 14, 3506-3512.	2.6	30
21	The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. <i>Oncotarget</i> , 2015, 6, 34910-34923.	1.8	52
22	The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. <i>Oncotarget</i> , 2015, 6, 26599-26614.	1.8	42
23	LTX-315 (Oncopore [®] , [®]). <i>Oncolimmunology</i> , 2014, 3, e29181.	4.6	46
24	Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 601-613.	4.2	70
25	The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. <i>Journal of Peptide Science</i> , 2004, 10, 37-46.	1.4	65
26	Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. <i>Journal of Peptide Science</i> , 2003, 9, 300-311.	1.4	44
27	Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilicN-terminal modifications. <i>Journal of Peptide Science</i> , 2003, 9, 510-517.	1.4	43
28	The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. <i>Journal of Peptide Science</i> , 2002, 8, 36-43.	1.4	38
29	Antimicrobial activity of short arginine- and tryptophan-rich peptides. <i>Journal of Peptide Science</i> , 2002, 8, 431-437.	1.4	131
30	Antibacterial activity of 15-residue lactoferricin derivatives. <i>Chemical Biology and Drug Design</i> , 2000, 56, 265-274.	1.1	125
31	Construction and synthesis of lactoferricin derivatives with enhanced antibacterial activity. <i>Journal of Peptide Science</i> , 1999, 5, 32-45.	1.4	71
32	A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes. <i>Journal of Leukocyte Biology</i> , 1995, 58, 575-581.	3.3	69
33	Effect of marine oils supplementation on coagulation and cellular activation in whole blood. <i>Lipids</i> , 1995, 30, 1111-1118.	1.7	50
34	Th1 clones that suppress IgG2ab specifically recognize an allopeptide determinant comprising residues 435-451 of Î³2ab. <i>European Journal of Immunology</i> , 1993, 23, 2655-2660.	2.9	19